Table 1:
Demographic, clinical, and MR imaging characteristics of the cohort
| RRMS (n = 43) | SPMS (n = 15) | P Valuea | |
|---|---|---|---|
| Women (No.) (%) | 38 (88.4) | 11 (73.3) | .658 |
| Age (mean) (SD) (yr) | 52.8 (12.1) | 60.5 (6.7) | .023b |
| Disease duration (mean) (SD) (yr) | 15.2 (8.9) | 21.9 (8.3) | .014b |
| EDSS (median) (IQR) | 3.0 (2.0–3.5) | 6.0 (3.6–6.5) | .003b |
| Age at onset (mean) (SD) (yr) | 37.6 (12.0) | 38.7 (8.5) | .428 |
| Disease-modifying therapy (No.) (%) | |||
| Interferon β-1a I.M. | 14 (32.6) | 2 (13.3) | .111 |
| Interferon β-1a S.C. | 3 (9.3) | 0 (0) | |
| Glatiramer acetate | 8 (18.6) | 2 (13.3) | |
| Natalizumab | 4 (9.3) | 1 (6.7) | |
| Dimethyl fumarate | 2 (4.7) | 0 (0) | |
| Fingolimod | 3 (7.0) | 0 (0) | |
| Teriflunomide | 1 (2.3) | 3 (20.0) | |
| Rituximab | 1 (2.3) | 0 (0) | |
| Ocrelizumab | 0 (0) | 1 (6.7) | |
| IVIG | 1 (2.3) | 1 (6.7) | |
| No therapy | 6 (14.0) | 5 (33.3) | |
| No. of LMCE foci | 1 (n = 33) | 1 (n = 8) | .292 |
| 2 (n = 8) | 2 (n = 4) | ||
| 3 (n = 2) | 3 (n = 3) | ||
| LMCE shape (No.) | .637 | ||
| Nodular | 36 | 16 | |
| Linear | 7 | 5 | |
| Plate-like | 12 | 4 | |
| T2 lesion volume (mean) (SD) (mL) | 16.0 (16.2) | 15.8 (11.4) | .965 |
| Gd lesion volume (median) (IQR) (mL) | 0 (0–0) | 0 (0–0) | .097 |
Note:—EDSS indicates Expanded Disability Status Scale; I.M., intramuscular; S.C., subcutaneous; IVIG, intravenous immunoglobulin; Gd, gadolinium.
a
P value represents differences between the patients with RRMS and SPMS. The differences between the groups were analyzed using the Fisher exact, Student t, Mann-Whitney U, or χ2 test.
b
P values < .05.